• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·CEVI.ST
Share

CellaVision AB Stocks

SEK 137.2Last Updated 12.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

SEK 315.83M

SEK 137.2
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

CellaVision AB (publ), a company established in Lund, Sweden, in 1994, specializes in the development and distribution of digital analytical solutions for blood and body fluid samples. Their offerings cater to the healthcare services sector, with a significant global presence spanning Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. The company's product portfolio includes advanced hardware such as the CellaVision DM1200 and CellaVision DM9600, which are designed to automatically capture digital images from blood smears and various body fluid preparations, alongside the CellaVision DC-1 analyzer. Complementing their instrumentation is a suite of specialized software applications. For instance, the CellaVision Peripheral Blood Application streamlines and standardizes the morphological examination of peripheral blood smears for laboratory professionals. Similarly, the CellaVision Advanced RBC Application facilitates a comprehensive evaluation of red blood cell morphology, while the CellaVision Body Fluid Application offers automated and standardized analysis for body fluid preparations. To enhance collaboration and flexibility, the CellaVision Remote Review Software eliminates geographical barriers in the smear review process. Further enriching their ecosystem are tools such as the CellaVision Server Software, which unifies workflows across single or multiple testing sites, and the CellaVision Dashboard, providing instant insights into analyzer and reviewer performance metrics. For staff development, the cloud-based CellaVision Proficiency Software aids laboratory managers in assessing and enhancing team competency in cell morphology. Educational resources include CellaVision CellAtlas, combining mini-lectures with an extensive cell image database. Finally, CellaVision VET extends their digital microscopy solutions to the field of veterinary hematology. Their clientele primarily consists of hospital and commercial diagnostic laboratories.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of CEVI.ST is 190 and suggests 44% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

13.06.2026 00:44

Retail investors bought $15 billion worth of SpaceX stock. Demand was at least 6 times that amount

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026